Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions

Nature Clinical Practice Oncology

Volumn 4, Issue 3, 2007, Pages 172-180

  Bentzen, Søren M ^a   Harari, Paul M ^a   Bernier, Jacques ^b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; AMIFOSTINE; CAMPTOTHECIN; CETUXIMAB; CISPLATIN; COMBRETASTATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; TAXANE DERIVATIVE; TEMOZOLOMIDE; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; XANTHONE 4 ACETIC ACID;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG DESIGN; HEAD AND NECK CARCINOMA; HUMAN; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

EID: 33847640529     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0744     Document Type: Review

References (81)

1. Jaffe N et al. (1976) Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38: 1925-1930
2. Hustu HO et al. (1968) Treatment of Ewing's sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr 73: 249-251
3. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91
4. Bernier J (2005) Alteration of radiotherapy fractionation and concurrent chemotherapy: A new frontier in head and neck oncology? Nat Clin Pract Oncol 2: 305-314
5. Ma BB et al. (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21: 2760-2776
6. Wilson GD et al. (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16: 2-9
7. Bentzen SM et al. (1989) Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol 56: 711-715
8. Denis F et al. (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55: 93-98
9. Trotti A and Bentzen SM (2004) The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22: 19-22
10. Bernier J and Bentzen SM (2003) Altered fractionation and combined radio-chemotherapy approaches: Pioneering new opportunities in head and neck oncology. Eur J Cancer 39: 560-571
11. Kim JJ and Tannock IF (2005) Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 5: 516-525
12. Bentzen SM (2003) Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol 79: 581-585
13. De Ruysscher D et al. (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24: 1057-1063
14. Whelan TJ (2005) Use of conventional radiation therapy as part of breast-conserving treatment. J Clin Oncol 23: 1718-1725
15. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360: 103-106
16. Schild SE et al. (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59: 943-951
17. Turrisi AT III et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271
18. Aviles A et al. (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45: 1385-1389
19. Dieckmann K et al. (2003) Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys 56: 644-652
20. van Rijn J et al. (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47: 779-784
21. Chinnaiyan P et al. (2006) Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, P13K, and Ras. Semin Radiat Oncol 16: 59-64
22. Munshi A et al. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922
23. Brunner TB et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-Ras. Cancer Res 65: 8433-8441
24. Erjala K et al. (2004) Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro. Acta Oncol 43: 169-174
25. Wong M et al. (2006) Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 24: 2448-2455
26. Edelstein MP et al. (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23 (Suppl 5): S41-S47
27. Zhang M et al. (2004) Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 58: 353-360
28. Nishimura Y (2004) Rationale for chemoradiotherapy. Int J Clin Oncol 9: 414-420
29. Brunner TB et al. (2003) Farnesyltransferase inhibitors as radiation sensitizers. Int J Radiat Biol 79: 569-576
30. Dey S et al. (2003) Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9: 1557-1565
31. Peters KB and Brown JM (2002) Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Res 62: 5248-5253
32. Tozer GM and Bicknell R (2004) Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 14: 222-232
33. Tozer GM et al. (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435
34. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62
35. Withers HR (1975) The four R's of radiotherapy. Adv Radiat Biol 5: 241-247
36. Harari PM and Huang SM (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49: 427-433
37. Milas L et al. (2003) Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park) 17 (Suppl 5): S15-S24
38. Bentzen SM (2006) Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6: 702-713
39. Trotti A (1998) Toxicity antagonists in head and neck cancer. Semin Radiat Oncol 8: 282-291
40. Spielberger R et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351: 2590-2598
41. Movsas B et al. (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23: 2145-2154
42. Brizel DM et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-3345
43. Bentzen SM et al. (2003) Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 13: 189-202
44. Green J et al. (2005) Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane Database Systematic Reviews, Issue 3, Art. No CD002225.
45. Trotti A (2000) Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47: 1-12
46. Bieri S et al. (2003) Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer: Experience from four nonrandomized studies. Strahlenther Onkol 179: 390-395
47. Bentzen SM and Bernier J (2002) Chemotherapy and altered fractionation in head-and-neck cancer: In regard to Staar et al., IJROBP 2001; 50: 1161-1171. Int J Radiat Oncol Biol Phys 52: 1423-1424
48. Cooper JS and Ang KK (2005) Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys 61: 7-9
49. Eng C et al. (2004) Chemotherapy and radiation of anal canal cancer: The first approach. Surg Oncol Clin N Am 13: 309-320, viii.
50. UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research (1996) Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348: 1049-1054
51. Bosset JF et al. (1997) Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups. Lancet 349: 205-206
52. Flam M et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14: 2527-2539
53. Thomas GM (2000) Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care. Semin Radiat Oncol 10: 44-50
54. Lukka H et al. (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta-analysis. Clin Oncol (R Coll Radiol) 14: 203-212
55. Zatloukal P et al. (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46: 87-98
56. Vokes EE et al. (2005) Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 11 (Suppl 2): S5045-S5050
57. Browman GP et al. (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 23: 579-589
58. Bernier J and Bourhis J (2005) Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment. Ann Oncol 16: 1722
59. Cooper JS et al. (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944
60. Bernier J et al. (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952
61. Wadsley JC and Bentzen SM (2004) Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 60: 1405-1409
62. Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578
63. Bentzen SM et al. (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560-5567
64. Koukourakis MI et al. (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727-735
65. Nordsmark M et al. (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77: 18-24
66. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
67. Forastiere AA et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098
68. Remenar E et al. (2006) A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): Final analysis of EORTC 24971 [abstract]. J Clin Oncol 24: 5516
69. Dunne AL et al. (2004) Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action. Oncol Res 14: 447-454
70. Ataman OU et al. (2004) Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 40: 2734-2741
71. Belbin TJ et al. (2002) Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62: 1184-1190
72. Buffa FM et al. (2004) Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10: 3745-3754
73. Chung CH et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500
74. Salesiotis AN and Cullen KJ (2000) Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: Evolution of a model beyond TNM staging. Curr Opin Oncol 12: 229-239
75. Bentzen SM (2005) Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77: 227-230
76. Moran JM et al. (2005) Radiotherapy: What can be achieved by technical improvements in dose delivery? Lancet Oncol 6: 51-58
77. Bentzen SM (2005) Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6: 112-117
78. Stupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996
79. Schaake-Koning C et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530
80. Rischin D et al. (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24: 2098-2104
81. Bentzen SM (2003) A user's guide to evidence-based oncology. Eur J Cancer Suppl 6: S77-S91